BioCentury
ARTICLE | Company News

ChemoCentryx, GlaxoSmithKline deal

December 9, 2013 8:00 AM UTC

ChemoCentryx said GlaxoSmithKline returned rights to CCX354, a CC chemokine receptor 1 (CCR1) antagonist that has completed Phase II testing for rheumatoid arthritis (RA). Last year, GSK exercised an option under a 2006 deal to license rights to CCX354, but ChemoCentryx said the pharma did not conduct any further clinical development of the compound. ChemoCentryx said it is too soon to discuss future development plans for CCX354 but noted the company has identified a "more potent" next-generation series of CCR1 inhibitors, which it is looking to partner.

GSK also declined to exercise its option for CCX168, a small molecule complement receptor 5a (C5aR; CD88) inhibitor in the Phase II CLEAR trial for antineutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis. ...